Myopia (Nearsightedness)

1. Comprehensive Executive Overview

Myopia, commonly referred to as nearsightedness, is a highly prevalent refractive error of the eye classified under ICD-10 code H52.1. It is characterized by the optical state in which parallel light rays entering the non-accommodating eye focus anterior to the photoreceptor layer of the retina. This mismatch between the refractive power of the anterior segment (cornea and crystalline lens) and the axial length of the globe results in clear near vision but blurred distance vision.

   [Parallel Light Rays] ---> [ Cornea / Lens ] ---> (Focal Point) ---> [ Retina ]
                                                     (Anterior to Retina)

Globally, myopia has transitioned from a simple refractive variation to a major public health crisis. Epidemiological models project that by the year 2050, approximately 50% of the world’s population (nearly 5 billion people) will be myopic, with 10% falling into the category of high myopia (spherical equivalent of $-6.00\text{ Diopters (D)}$ or worse, or an axial length $\ge 26.5\text{ mm}$).

While mild to moderate myopia can be easily corrected with optical devices, high and progressive myopia are associated with pathological structural changes in the ocular fundus. These structural changes can lead to irreversible vision loss through conditions such as myopic macular degeneration (MMD), retinal detachment, primary open-angle glaucoma (POAG), and premature cataract formation. Consequently, modern ophthalmology focuses heavily on early diagnostic intervention and active myopia control strategies in pediatric patients.

2. Detailed Pathophysiology, Etiology, and Risk Factors

To understand the development of myopia, one must examine the delicate process of emmetropization—the mechanism by which the infantile eye coordinates its axial growth with the refractive power of its optical components to achieve a state of perfect focus (emmetropia).

Pathophysiology of Axial Elongation

In the myopic eye, this feedback loop is disrupted. The primary structural driver of myopia is excessive axial elongation of the vitreous chamber.

• Scleral Remodeling: The sclera, composed of a dense extracellular matrix (ECM) of Type I collagen, proteoglycans, and glycoproteins, undergoes active remodeling. In a myopic eye, there is an upregulation of matrix metalloproteinases (specifically MMP-2) and a downregulation of tissue inhibitors of metalloproteinases (TIMPs). This enzymatic imbalance leads to collagen degradation, thinning of the posterior scleral shell, and increased scleral extensibility.
• Peripheral Retinal Defocus: The retina acts as the detector of image quality, sending biochemical signals through the retinal pigment epithelium (RPE) and choroid to the sclera. If the peripheral retina experiences hyperopic defocus (where peripheral light rays focus behind the retina, a common side effect of standard single-vision corrective lenses), it triggers signaling cascades (involving dopamine, retinoic acid, and transforming growth factor-beta [TGF-$\beta$]) that accelerate scleral elongation to move the retina back to the focal plane.

Etiology

The etiology of myopia is multifactorial, involving a complex interplay between genetic susceptibility and environmental influences:

1. Genetic Factors: Over 200 genetic loci associated with refractive error and myopia have been identified through Genome-Wide Association Studies (GWAS). These genes influence extracellular matrix remodeling, light-transduction pathways, and eye development. A child with one myopic parent has a threefold increased risk of developing the condition; this risk increases to fivefold if both parents are myopic.
2. Environmental Pressures:
3. Intense Near-Work Activities: Prolonged reading, screen time, and close-up tasks place a high demand on accommodation and convergence, inducing transient accommodation lag and subsequent hyperopic defocus.
4. Deprivation of Outdoor Light: Insufficient exposure to natural sunlight is a primary environmental driver. Bright outdoor light (typically $>10,000\text{ lux}$) stimulates the release of retinal dopamine. Dopamine acts as an inhibitor of axial elongation; low light levels indoors fail to trigger this protective pathway.

3. Signs, Symptoms, and Clinical Presentation

The clinical presentation of myopia varies based on the patient's age, the degree of refractive error, and whether pathological structural changes have initiated.

Subjective Symptoms

• Distance Blur: The hallmark symptom. Patients report difficulty seeing road signs, blackboards in classrooms, or faces across a room.
• Asthenopia (Eye Strain) & Headaches: Often caused by chronic squinting. Squinting creates a stenopeic slit effect (acting like a pinhole camera) to temporarily reduce the blur circle on the retina, but it leads to fatigue of the orbicularis oculi and extraocular muscles.
• Night Myopia: Increased blur under low-light conditions. This is driven by pupil dilation (mydriasis), which exposes peripheral optical aberrations of the cornea and lens, and the Purkinje shift toward shorter wavelengths of light.

Objective Clinical Signs

During a clinical evaluation, the ophthalmologist or optometrist will observe:
* Decreased Uncorrected Visual Acuity (UCVA): Distance visual acuity is worse than 20/20, while near visual acuity remains 20/20 or better (unless pathology is present).
* Deep Anterior Chamber: Axial myopes often present with a deeper anterior chamber and wider iridocorneal angles.
* Fundus Changes (in High/Pathologic Myopia):
* Tessellated Fundus: Prominent choroidal vessels visible due to thinning of the overlying RPE.
* Myopic Crescent (Temporal Crescent): A crescent-shaped area of sclera or choroid exposed adjacent to the optic nerve head, caused by the stretching of the ocular coats.
* Posterior Staphyloma: An outpouching of the posterior ocular wall, a hallmark of pathologic myopia.
* Lattice Degeneration: Areas of peripheral retinal thinning, which predispose the patient to retinal tears and rhegmatogenous retinal detachment.

4. Standard Diagnostic Evaluation & Workup

A comprehensive ophthalmic workup is essential not only to quantify the refractive error but also to evaluate the structural integrity of the globe and monitor progression.

[Patient Presentation]
│
▼
[Visual Acuity Testing] ──► [Cycloplegic Refraction] ──► [Optical Biometry (Axial Length)]
│
▼
[Dilated Fundus Exam] ──► [Peripheral Retina Check] & [Optical Coherence Tomography (OCT)]

1. Refraction (The Gold Standard)

• Manifest (Subjective) Refraction: Determines the lens combination that provides the sharpest visual acuity. Care must be taken to avoid over-minifying the patient, which occurs when the examiner prescribes too much minus power, forcing the patient to use their accommodation to clear the image.
• Cycloplegic Refraction: This is the absolute gold standard for pediatric patients and young adults. By instilling cycloplegic drops (such as Cyclopentolate 1% or Atropine 1%), the ciliary muscle is temporarily paralyzed, eliminating accommodation. This reveals the true static refractive error of the eye and prevents the misdiagnosis of "pseudo-myopia" caused by accommodative spasms.

2. Ocular Biometry (Axial Length Measurement)

Using non-contact optical biometry (e.g., IOLMaster or Lenstar) based on optical coherence interferometry, the clinician measures the axial length from the anterior corneal surface to the RPE.
* Clinical Significance: Monitoring axial length is the most precise way to track myopia progression and assess the efficacy of myopia-control interventions. An increase of $0.1\text{ mm}$ in axial length corresponds to approximately $-0.25\text{ D}$ of myopic shift.

3. Slit-Lamp Biomicroscopy and Tonometry

• Evaluation of the anterior segment to rule out secondary causes of myopia (e.g., keratoconus, anterior lenticonus).
• Goldmann Applanation Tonometry (GAT) is performed to measure intraocular pressure (IOP), as myopic eyes have a statistically higher risk of developing open-angle glaucoma.

4. Dilated Fundus Examination (DFE)

Using binocular indirect ophthalmoscopy with a 28D or 90D condensing lens through a fully dilated pupil (using Tropicamide 1% and Phenylephrine 2.5%). The peripheral retina must be thoroughly examined to identify:
* Lattice degeneration
* Atrophic retinal holes
* Horseshoe tears
* Subretinal neovascularization (myopic choroidal neovascularization [mCNV])

5. Advanced Structural Imaging

• Optical Coherence Tomography (OCT): High-resolution cross-sectional imaging of the macula to screen for myopic traction maculopathy, macular holes, and dome-shaped macula.
• Fundus Autofluorescence (FAF): Used to map areas of RPE atrophy in pathologic myopia.

5. Therapeutic Interventions

Management of myopia is divided into two clinical objectives: optical correction of the refractive error to restore visual acuity, and myopia control to slow down axial elongation in pediatric patients.

A. Refractive Correction (Acutely Restoring Vision)

1. Spectacle Lenses: Concave (minus) lenses diverge incoming light rays so they focus precisely on the retina.
2. Contact Lenses: Soft or rigid gas-permeable (RGP) lenses provide superior peripheral vision and eliminate the minification associated with high-power spectacle lenses.

B. Pediatric Myopia Control (Slowing Progression)

These treatments are initiated in children showing rapid progression (typically $>0.50\text{ D}$ or $>0.2\text{ mm}$ of axial growth per year).

1. Pharmacotherapy: Low-Dose Atropine

Atropine is a non-selective muscarinic antagonist. While its exact mechanism is still being researched, it is believed to act directly on receptors in the retina, RPE, or sclera to inhibit scleral remodeling, independent of its effect on accommodation.
* Dosing Regimen: Atropine 0.01%, 0.025%, or 0.05% ophthalmic drops instilled nightly.
* Efficacy: Clinical trials (LAMP and ATOM studies) demonstrate a 30% to 50% reduction in the rate of myopic progression, with the 0.05% concentration showing the most favorable balance of efficacy and minimal side effects (mild pupillary dilation and near blur).

2. Optical Myopia Control Devices

• Orthokeratology (Ortho-K): Specialized reverse-geometry rigid gas-permeable contact lenses worn overnight. They temporarily reshape the central corneal epithelium (flattening it) to correct daytime myopia, while steepening the mid-peripheral cornea. This mid-peripheral steepening creates peripheral myopic defocus, which acts as a powerful stop-signal for axial elongation.
• Dual-Focus Soft Contact Lenses (e.g., MiSight): Daily disposable lenses featuring concentric rings of distance correction alternating with treatment zones that introduce $+2.00\text{ D}$ of myopic defocus.

• Defocus Incorporated Multiple Segments (DIMS) Spectacle Lenses: Spectacle lenses containing a central zone for distance correction surrounded by a honeycomb-like zone of defocus segments.

  [ Incoming Light ] ──► [ Central Cornea (Flattened) ] ──► Focuses on Macula (Clear Vision)
  ──► [ Mid-Peripheral Cornea ] ──► Focuses in Front of Retina (Myopic Defocus)

C. Refractive Surgery (For Adults with Stable Refraction)

Once refractive stability is achieved (typically after age 18 to 21, confirmed by stable refractions for at least 12 months), surgical options can be explored:

1. Corneal Laser Procedures

• LASIK (Laser-Assisted in Situ Keratomileusis): A microkeratome or femtosecond laser creates a thin corneal flap, and an excimer laser ablates the underlying stromal tissue to flatten the central cornea.
• PRK (Photorefractive Keratectomy): Surface ablation where the corneal epithelium is removed, and the laser acts directly on the anterior stroma. Ideal for patients with thin corneas or ocular surface issues.
• SMILE (Small Incision Lenticule Extraction): A femtosecond laser carves a refractive lenticule within the intact corneal stroma, which is manually extracted through a microscopic incision. This preserves corneal biomechanical strength better than LASIK.

2. Intraocular Procedures

• Phakic Intraocular Lenses (e.g., Implantable Collamer Lens - ICL): A collamer lens is surgically inserted into the posterior chamber of the eye, behind the iris and in front of the natural crystalline lens. This is the treatment of choice for high myopia ($-8.00\text{ D}$ to $-20.00\text{ D}$) or when the cornea is too thin for laser surgery.
• Refractive Lens Exchange (RLE): Removal of the natural crystalline lens and replacement with an intraocular lens (IOL). Typically reserved for presbyopic patients with high myopia.

D. Lifestyle Modifications

• Outdoor Activity: Prescribing at least 120 minutes of outdoor play daily under natural sunlight. This is one of the most effective, evidence-based methods to prevent the onset of myopia in children.
• The 20-20-20 Rule: For every 20 minutes of near work, look at an object 20 feet away for at least 20 seconds to relax accommodation.

6. Frequently Asked Questions (FAQs)

1. What is the difference between progressive myopia and stable myopia?

Progressive myopia occurs when the refractive error continues to worsen year over year, typically during childhood and adolescence, driven by rapid axial elongation of the eyeball. Stable myopia is when the refractive error remains constant, fluctuating by less than $0.25\text{ D}$ per year, which usually occurs once skeletal maturity is reached (between ages 18 and 21).

2. Can myopia be cured permanently without surgery?

No. There is no natural cure, exercise, or diet that can reverse the physical elongation of the eyeball once it has occurred. Non-surgical options like spectacles, contact lenses, and Orthokeratology manage and correct the visual symptoms or slow down progression, but only refractive surgery (like LASIK or ICL) can permanently alter the eye's optics to eliminate the need for corrective lenses.

3. Why does high myopia increase the risk of retinal detachment?

In high myopia (usually defined as $>-6.00\text{ D}$), the eyeball is physically longer than normal. This stretching pulls the retina, choroid, and sclera thin, especially in the far periphery. This thinning can lead to the development of lattice degeneration, retinal holes, or tears. If a tear occurs, vitreous fluid can seep underneath, peeling the retina away from its underlying pigment epithelium, causing a rhegmatogenous retinal detachment.

4. At what age does myopia progression typically stop?

For most individuals, myopia progression slows down and stabilizes between the ages of 18 and 21. This stabilization coincides with the cessation of general physical growth. However, in cases of pathologic myopia, progressive elongation can continue well into adulthood.

5. How does low-dose atropine help slow down myopia in children?

Low-dose atropine (0.01% to 0.05%) blocks muscarinic receptors in the eye. While it does mildly dilate the pupil, its primary therapeutic effect comes from biochemical signaling pathways in the retina and sclera. It slows down the remodeling of the scleral extracellular matrix, thereby reducing the rate of axial elongation of the eyeball.

6. What is Orthokeratology (Ortho-K) and how does it work?

Orthokeratology involves wearing custom-designed, oxygen-permeable rigid contact lenses overnight. While sleeping, these lenses gently reshape the outer layer of the cornea (the epithelium). When the lenses are removed in the morning, the reshaped cornea focuses light perfectly on the retina, providing clear vision throughout the day without glasses or daytime contacts. It also creates peripheral myopic defocus, which helps slow down eye growth in children.

7. Is LASIK surgery safe for everyone with myopia?

No. LASIK is highly safe and effective, but only for candidates who meet strict criteria. Contraindications include an unstable prescription over the past year, corneas that are too thin or irregularly shaped (e.g., keratoconus), severe dry eye syndrome, active ocular infections, or systemic conditions that impair healing (like uncontrolled autoimmune diseases).

8. What is the difference between axial myopia and refractive myopia?

• Axial myopia is caused by an eyeball that is physically too long from front to back, while the focusing power of the cornea and lens is normal.
• Refractive myopia occurs when the physical length of the eyeball is normal, but the cornea is too curved (steep) or the crystalline lens has too much focusing power (often due to early cataract changes).

9. How does outdoor light exposure prevent the onset of myopia?

Natural sunlight stimulates the release of the neurotransmitter dopamine from the retina. Dopamine acts as a natural inhibitor of axial elongation of the eye. Indoor lighting is significantly dimmer than natural daylight and does not trigger this protective dopamine release, which allows the eye to grow unchecked under near-work stress.

10. What are the signs of pathologic or degenerative myopia?

Pathologic myopia is characterized by progressive, degenerative changes in the posterior segment of the eye. Signs include:
* The formation of a posterior staphyloma (an outpouching of the sclera)
* Lacquer cracks (ruptures in Bruch's membrane)
* Myopic choroidal neovascularization (growth of abnormal, leaky blood vessels under the retina)
* Patchy chorioretinal atrophy
* A progressive decrease in best-corrected visual acuity (BCVA) that cannot be corrected with glasses alone.

Related Clinical Integration

In a modern clinical setting, the management of myopia often extends beyond refractive correction with spectacles or contact lenses to include surgical interventions aimed at permanent vision correction. For patients seeking to reduce or eliminate their dependence on corrective eyewear, our hospital offers advanced refractive procedures such as LASIK (Laser-Assisted In Situ Keratomileusis) / الليزك (تعديل تحدب القرنية بالليزر في الموضع) (عملية صغرى في العيادة), which reshapes the cornea to improve visual acuity. For individuals who may not be ideal candidates for LASIK due to corneal thickness or other anatomical factors, we provide PRK (Photorefractive Keratectomy) / استئصال القرنية الانكساري الضوئي (PRK) (عملية صغرى في العيادة) as a safe and effective alternative. These procedures are integrated into our comprehensive ophthalmic care pathway to ensure that patients receive personalized treatment plans tailored to their specific refractive needs and ocular health profiles.